Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIM0500 in Relapsed or Refractory Multiple Myeloma
NCT06375044Phase 1Recruiting
- Sponsor
- Simcere Pharmaceutical Group
- Start
- May 2024
- Primary completion
- Sep 2027
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Trispecific Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of SIM0500 in multiple myeloma (MM), sponsored by Simcere Pharmaceutical Group. Primary endpoints: Dose-limiting toxicity at 35 days and Adverse Events at 24 months. Started May 2024; status: recruiting.
02
Drugs
SIM0500
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06375044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06375044.